Menu Back toSession 5: Emerging EU HTA - Will Joint Scientific Consultations and Joint Clinical Assessments on the European level enable faster and broader patient access to ATMPs?

Innovative Therapies in Europe

DIA-EUCOPE Workshop: 5 Years of ATMPs on the Market - Lessons Learned

Session 5: Emerging EU HTA - Will Joint Scientific Consultations and Joint Clinical Assessments on the European level enable faster and broader patient access to ATMPs?

Session Chair(s)

Vanessa Elisabeth Schaub

Vanessa Elisabeth Schaub

  • Global Access Senior Health Systems Strategy Leader HTA & Reimbursement
  • F. Hoffmann-La Roche, Switzerland

Topics covered in this session include:

  • What is the EC’s vision for accelerated patient access in Europe by moving to a European HTA approach?
  • How a flexible yet predictable should HTA approach for ATMPs look like?
  • Will JSC help early alignment for non-traditional evidence requirements and needs?
  • Which role will RWE & Registries play along the product life cycle to close data gaps?

Speaker(s)

Emil Andrei Cochino, MD, MHS

Emil Andrei Cochino, MD, MHS

  • Scientific Officer, Risk Management Specialist, Office of vaccines and therapies
  • European Medicines Agency, Netherlands
Marcus Guardian

Marcus Guardian

  • COO EUnetHTA 21, General Manager - Heads of HTA Agencies Group
  • EUnetHTA, Netherlands
Maria João Garcia, PharmD

Maria João Garcia, PharmD

  • Global Access Evidence Lead
  • F. Hoffmann-La Roche, Ltd., Switzerland

Contact us

Registration Questions?

Send Email
+41 61 225 51 51